9 clinical trials found.
-
A phase III multicenter randomized open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive HER2-negative early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).
The purpose of the trial is to evaluate the efficacy and the safety of ribociclib when given in combination with endocrine (hormonal) therapy, compared to ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer (IBC)
The purpose of this study is to determine whether the addition of nivolumab to chemotherapy improves response rate in patients with inflammatory breast cancer (IBC ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy of Node Positive HER2 Negative Breast Cancer: The ABC Trial
If you have been diagnosed with breast cancer and have completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer, you may qualify ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
S1418/BR006 A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
If you have been diagnosed with triple negative breast cancer (TNBC) you may qualify to participate in a clinical trial investigating the investigational drug MK-3475 ...
Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A randomized phase II trial of fulvestrant with or without Ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive HER2 negative breast cancer
This is a phase II, multi-center, randomized, double-blind, placebo-controlled trial to evaluate fulvestrant +/- ribociclib in patients with HR+HER2- breast cancer who have previously progressed ...
Phase
Interventional
TRIAL ROLE: Sub Investigator
-
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
The goal of this Phase II study is to evaluate the safety/tolerability and clinical activity of the combination of nab-paclitaxel and the antibody against ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
Prone Partial Breast Irradiation (PBI): A Prospective Randomized Trial Comparing Five Versus Three Fractions
If you have been diagnosed with Stage 0 or I breast cancer, also known as ductal carcinoma in situ (DCIS) or T1 breast cancer, you ...
Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Multicenter Phase I/II Trial of Anastrozole Palbociclib Trastuzumab and Pertuzumab in HR-positive Her2-positive Metastatic Breast Cancer (ASPIRE)
The purpose of this study is to assess the safety and effectiveness of giving anastrozole, palbociclib, trastuzumab and pertuzumab to women with hormone receptor (HR ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A PHASE 3 MULTICENTER RANDOMIZED OPENLABEL ACTIVE-CONTROLLED TRIAL OF DS-8201A AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN S CHOICE FOR HER2LOW UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS
This is a randomized Phase 3, open-label, multicenter study to compare the safety and efficacy of DS-8201a versus the physician’s choice in HER2-low, unresectable ...Phase
Interventional
TRIAL ROLE: Sub Investigator
